NetScientific (NSCI), the investment and commercialisation group with an international portfolio of innovative life science, sustainability, and technology companies, reported yesterday that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company, announced its Q4 2022 and FY 2022 results.
29 Mar 2023
NetScientific (NSCI) – Corporate – PDS Biotech business update and Q4 2022 / FY
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
NetScientific (NSCI) – Corporate – PDS Biotech business update and Q4 2022 / FY
NetScientific plc (NSCI:LON) | 67.0 0 0.0% | Mkt Cap: 16.0m
- Published:
29 Mar 2023 -
Author:
Matthew Davis | Emma Ulker -
Pages:
5
NetScientific (NSCI), the investment and commercialisation group with an international portfolio of innovative life science, sustainability, and technology companies, reported yesterday that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company, announced its Q4 2022 and FY 2022 results.